Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial
Raja Atreya, Tanja Kühbacher, Michael Vieth, André Jefremow et autres